8-[3-[(p-isobutyloxycarbonyl)-phenoxy]-propylthio]-adenosine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 8-[3-[(p-isobutyloxycarbonyl)-phenoxy]-propylthio]-adenosine
• 英文别名: 2-methylpropyl 4-[3-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-8-yl]sulfanylpropoxy]benzoate
• 化学式: C₂₄H₃₁N₅O₇S
• 分子量: 533.605
• InChiKey: ADEIUWZFTPTHDF-WGQQHEPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  200
• 氢给体数：
  4
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  尼泊金异丁酯 在 sodium isobutoxide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 8-[3-[(p-isobutyloxycarbonyl)-phenoxy]-propylthio]-adenosine
  参考文献：
  名称：

  8-Substituted purine derivatives: a new class of lipid-lowering agents

  摘要：

  A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested. Some compounds, among which 8-{2-(R)-hydroxy-3-[(p-isobutoxycarbonyl)phenoxy]propylthio}adenosine 31, 8-{3-[(p-isobutoxy carbonyl)phenoxy]-2-oxopropylthio} adenosine 33 and 8-{3-[(p-isobutoxycarbonyl)phenoxy]-2-hydrazonecarboxamidepropylthio} adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg. Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein/low density lipoprotein) cholesterol levels by 10-33% and 13-46%, respectively, and increase HDL-associated cholesterol levels by 10-32%. These molecules have been chosen for further pharmacological and toxicological evaluations.

  DOI：

  10.1016/0223-5234(94)90098-1

文献信息

• Derivatives of (hetero) aromatic ethers and thioethers having antihyperlipidemic activity, process for their preparation and pharmaceutical compositions containing them
  申请人：PIERREL S.p.A.

  公开号：EP0520552A1

  公开（公告）日：1992-12-30

  The novel derivatives of (hetero)aromatic ethers and thioethers represented by the following general formula I:         (HET)Ar-X-CH₂-Y-CH₂-O-R   (I) wherein: (HET)Ar represent a mono-,bi- and tri-cyclic aryl or hetero aryl nucleous possibly substituted, X represents -O- or -S-; Y represents -CO-, a linear or branched polymethylene having 0 to 8 carbon atoms with the proviso that it is not (CH₂)n in which 0

  以下是一般公式 I 所表示的 (杂)芳香醚和硫醚的新型衍生物：          (HET)Ar-X-CH₂-Y-CH₂-O-R         (I) 其中： (HET)Ar 表示可能带有取代基的单环、双环和三环芳基或杂芳基核； X 代表 -O- 或 -S-； Y 代表 -CO-，具有 0 到 8 个碳原子的直链或支链聚亚甲基，条件是当 (HET)Ar 表示可能用甲基和/或硝基取代的咪唑环，并且同时 X = S，-CH(OR₁)，其中 R₁ 是氢或来自脂肪族、芳香族或杂环羧酸的酰基，条件是当 (HET)Ar 表示鸟嘌呤、腺嘌呤或腺苷基团时，R₁ 不是氢，-C=N-R₂，其中 R₂ 是氢或具有 1 到 10 个碳原子的直链或支链烷基，OH，具有 1 到 10 个碳原子的烷氧基，芳氧基，芳烷氧基，-NH₂，-NHCONH₂，-NHCSNH₂；且 R 代表在间位带有羧基或 (C₁-C₂0) 烷氧甲酸基的苯基，其中烷氧基可以是直链或支链的，具有抗高脂血症活性。 此外，还描述了它们的制备过程和含有它们的药物组合物。
• 8-Substituted purine derivatives: a new class of lipid-lowering agents
  作者：E Vanotti、M Bani、D Favara、M Gobetti、M Lombroso、S Magnetti、V Olgiati、M Palladino、GC Tonon

  DOI：10.1016/0223-5234(94)90098-1

  日期：1994.1

  A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested. Some compounds, among which 8-2-(R)-hydroxy-3-[(p-isobutoxycarbonyl)phenoxy]propylthio}adenosine 31, 8-3-[(p-isobutoxy carbonyl)phenoxy]-2-oxopropylthio} adenosine 33 and 8-3-[(p-isobutoxycarbonyl)phenoxy]-2-hydrazonecarboxamidepropylthio} adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg. Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein/low density lipoprotein) cholesterol levels by 10-33% and 13-46%, respectively, and increase HDL-associated cholesterol levels by 10-32%. These molecules have been chosen for further pharmacological and toxicological evaluations.